Thymosin beta 4: An emerging therapeutic candidate for kidney diseases

Area of Science:

• Nephrology
• Molecular Biology
• Biochemistry

Background:

• Kidney disease presents a growing global health challenge, necessitating novel therapeutic approaches.
• Thymosin β4 (Tβ4), a key cellular regulator, and its metabolite N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) are implicated in renal injury and repair processes.
• Tβ4's role has expanded beyond actin sequestration to encompass complex cellular homeostasis and repair mechanisms.

Purpose of the Study:

• To review and synthesize current knowledge on the Tβ4-Ac-SDKP axis in kidney disease.
• To elucidate the mechanisms, expression patterns, and renoprotective effects of Tβ4 and Ac-SDKP.
• To evaluate translational opportunities and challenges for Tβ4-based therapies.

Main Methods:

• Literature review synthesizing evidence on the Tβ4-Ac-SDKP axis.
• Analysis of intra- and extracellular mechanisms and signaling pathways.
• Evaluation of renoprotective efficacy in acute and chronic kidney injury models.

Main Results:

• Tβ4 and Ac-SDKP exhibit cytoprotective, anti-inflammatory, and antifibrotic actions in kidney injury models.
• Expression patterns of Tβ4 and Ac-SDKP vary across glomerular and tubular compartments.
• Bidirectional effects on fibrosis and model-dependent mechanisms require reconciliation.

Conclusions:

• The Tβ4-Ac-SDKP axis represents a promising therapeutic target for kidney diseases.
• Further validation in diverse models and optimization of peptide stability and delivery are crucial.
• Comprehensive safety assessments are necessary for clinical translation.